pharmacokinetics of anti-tuberculosis drugs in hiv-positive and hiv-negative adults in malawi
DESCRIPTION
Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi. J.J. van Oosterhout 1,2 , F. Dzinjalamala 3 , A. Dimba 4 , D. Waterhouse 5 , G. Davies 6,7 , M. Molyneux 5,6 , E. Molyneux 8 , S. Ward 7 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/1.jpg)
Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi
J.J. van Oosterhout 1,2, F. Dzinjalamala 3, A. Dimba 4, D. Waterhouse 5, G. Davies 6,7, M. Molyneux 5,6, E. Molyneux 8, S. Ward7
1College of Medicine, Department of Medicine, Blantyre, Malawi,2Dignitas International, Zomba, Malawi,3 College of Medicine, Department of Biochemistry, Blantyre, Malawi, 4National Tuberculosis Control Program, Lilongwe, Malawi, 5Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 6Malawi-Liverpool-Wellcome Trust Clinical Research Programme Unit, Blantyre, Malawi, 7University of Liverpool, Liverpool, United Kingdom, 8College of Medicine, Department of Pediatrics, Blantyre, Malawi
![Page 2: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/2.jpg)
Background• High HIV prevalence and high TB-HIV co-infection rate in Malawi• High prevalence of malnutrition• Few pharmacokinetic studies of TB drugs sub-Saharan Africa• Some data suggest HIV infection affects TB drug levels
Aims• Pharmacokinetic profiles of 4 drugs of Malawi first line TB treatment
regimen (RHZE)• Impact of HIV status and other factors on TB drug pharmacokinetics
![Page 3: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/3.jpg)
Methods• Intensive PK study adult Malawians • Sputum AFB smear positive PTB• Intensive phase TB treatment
• Exclusion: vomiting, diarrhea; Hb <8.0 g/dL; recent stop ART
• FDC formulations; dosing according to recommended weight bands
• Sampling: 0 – 0.5 – 1 – 2 – 3 – 4 – 6 – 8 – 24
• R and Z: high-performance liquid chromatography• H and E: mass spectrometry
![Page 4: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/4.jpg)
Patient characteristics • N=47
• 51% male
• Mean age 34
• 30 (65%) HIV+
• Median CD4 = 167 (53% <200) cells/µL
• 14 (47%) on ART
• Median weight 54.5 kg
• Median BMI 19.2 (46% <18.5)
![Page 5: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/5.jpg)
Results compatible with other studies from the region
A. Tostmann et al; AAC 2013. B. McIlleron et al; AAC 2006. C. Saleri et al; JAC 2012
![Page 6: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/6.jpg)
No significant impact on main PK parameters:
•Dose, weight, weight-adjusted dose, gender, age
•HIV infection, being on ART
![Page 7: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/7.jpg)
Potential causes of low rifampicin exposure
•Dose–weight •Malnutrition •HIV infection• Severe illness• Sample collection/transport
•Breakfast•Pharmaco-genetic factors• SLCO1B1 polymorphisms
•Quality of drug formulation
![Page 8: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/8.jpg)
Conclusions:- PK results comparable to SSA studies low rifampicin exposure- No impact of HIV infection
Acknowledgements: National TB Control Programme; University of Liverpool
![Page 9: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/9.jpg)
![Page 10: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/10.jpg)
![Page 11: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/11.jpg)
8-24 3-5 20-50 2-6
![Page 12: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/12.jpg)
![Page 13: Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi](https://reader036.vdocuments.us/reader036/viewer/2022062517/56813c65550346895da5f21c/html5/thumbnails/13.jpg)